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Abstract
Background/Aims: Pim-1 is a serine/threonine kinase that is highly expressed in the heart,
and exerts potent cardiac protective effects through enhancing survival, proliferation,
and regeneration of cardiomyocytes. Its myocardial specific substrates, however, remain
unknown. In the present study, we aim to investigate whether Pim-1 modulates myofilament
activity through phosphorylation of cardiac troponin I (cTnI), a key component in regulating
myofilament function in the heart. Methods: Coimmunoprecipitation and immunofluorescent
assays were employed to investigate the interaction of Pim-1 with cTnI in cardiomyocytes.
Biochemical, site directed mutagenesis, and mass spectrometric analyses were utilized to
identify the phosphorylation sites of Pim1 in cTnI. Myofilament functional assay using skinned
cardiac fiber was used to assess the effect of Pim1-mediated phosphorylation on cardiac
myofilament activity. Lastly, the functional significance of Pim1-mediated cTnI in heart disease
was determined in diabetic mice. Results: We found that Pim-1 specifically interacts with
cTnI in cardiomyocytes and this interaction leads to Pim1-mediated cTnI phosphorylation,
predominantly at Ser23/24 and Ser150. Furthermore, our functional assay demonstrated that
Pim-1 induces a robust phosphorylation of cTnI within the troponin complex, thus leading to
a decreased Ca2+ sensitivity. Insulin-like growth factor 1 (IGF-1), a peptide growth factor that
has been shown to stimulate myocardial contractility, markedly induces cTnI phosphorylation
at Ser23/24 and Ser150 through increasing Pim-1 expression in cardiomyocytes. In a highfat diabetic mice model, the expression of Pim1 in the heart is significantly decreased,
which is accompanied by a decreased phosphorylation of cTnI at Ser23/24 and Ser150,
further implicating the pathological significance of the Pim1/cTnI axis in the development of
diabetic cardiomyopathy. Conclusion: Our results demonstrate that Pim-1 is a novel kinase
that phosphorylates cTnI primarily at Ser23/24 and Ser150 in cardiomyocytes, which in turn
may modulate myofilament function under a variety of physiological and pathophysiological
conditions.
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Published by S. Karger AG, Basel
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Introduction

Pim-1 is a highly conserved serine/threonine kinase that belongs to the calmodulindependent protein kinase related group and prefers to phosphorylate the consensus
sequence (K/R)-(K/R)-(K/R)-X-(S/T)-X [1]. It is originally identified as a cellular oncogene
that inhibits apoptosis and promotes proliferation [1]. Recently, accumulating evidence
suggests that Pim-1 plays a pivotal role in protecting heart function from ischemia induced
damage and cardiac hypertrophy [2, 3], as well as protecting mitochondrial integrity in
cardiomyocyte [4]. Moreover, Pim-1-engineered cardiac progenitor cells dramatically
improve the cardiac function after myocardial infarction [5, 6]. Systemic delivery of human
Pim-1 via cardiotropic adeno-associated virus serotype-9 improves diabetic cardiomyopathy
by induction of prosurvival signaling [7]. Furthermore, Pim-1 has been shown to promote
cardiomyocyte survival and protect heart muscles from ischemic damage downstream of
Akt through regulating expression of anti-apoptotic proteins and calcium channels [8].
Notably, Pim-1 maintains cardiomyocyte contractility by increasing Ca2+ transient amplitude
and percentage of cell shortening in isolated cardiomyocyte [8]. However, the molecular
mechanisms underlying Pim-1-mediated cardiac contractility still remain unclear.
Cardiac troponin complex has three major components, cardiac troponin I (cTnI),
Troponin T (TnT), and Troponin C (TnC) [9, 10]. cTnI is the inhibitory unit that interacts
with the major proteins present in the sarcomeric thin ﬁlament, including actin, cTnC,
α-tropomyosin (α-TM), and cTnT [11]. These interactions reveal the pivotal roles of cTnI
in regulating heart muscle crossbridge kinetics and contraction in response to changes of
intracellular Ca2+ concentrations [12]. Phosphorylation of specific serine and threonine
residues on cTnI by several different kinases represents a major physiological mechanism for
alteration of myofilament properties. For example, cAMP-dependent protein kinase (PKA)
mediates phosphorylation of the two serine residues (Ser-23/24) in the unique N-terminal
domain of cTnI, leading to a reduction in myoﬁlament Ca2+ sensitivity and an increase in
crossbridge cycling rate by reducing the Ca2+-binding afﬁnity of cTnC [13]. Likewise, PKD1
phosphorylates cTnI at Ser-23/24, resulting in desensitization of the myofilament response
to Ca2+ as well as an increase in cross-bridge kinetics [14, 15]. Another important protein
kinase family, protein kinase C (PKC) is found to phosphorylate cTnI at Ser-23/24, Ser-43/45,
and Thr144 residues [16]. Phosphorylation of the Ser-43/45 sites depresses the maximum
tension and crossbridge kinetics, which is in contrast to phosphorylation of Ser-23/24
[17]. Moreover, the effect of phosphorylation at Ser-43/45/Thr144 dominates the effects
of phosphorylation at Ser-23/24 [18]. Other kinases such as P21-activated kinases (PAK)
have been found to cause phosphorylation of cTnI at Ser-149, which results in an increase
in myofilament Ca2+ sensitivity [19]. More recently, 5’-AMP kinase (AMPK) has been shown
to induce an increase in Ca2+ responsiveness of the myofilaments and blunt PKA-dependent
function through phosphorylation of Ser-150 of cTnI [20-22]. Importantly, by using mass
spectrometric (MS) approaches, Zhang et al. demonstrated that there is a depression in
phosphorylation at cTnI-Ser23/24 but an increase in phosphorylation of cTnI-Ser43/45 in
human ischemic and dilated cardiomyopathy [23]. Thus, alteration of cTnI phosphorylation
levels has a great clinical relevance that may shed light on the discovery of novel therapeutic
targets of heart failure.
Pim-1 is implicated in regulating cardiomyocyte contractility and calcium transient, the
role of Pim-1 in modulating cardiac myofilament activity, however, remains largely unknown
[8]. In the present study, we for the first time identified Pim-1 as a novel kinase that specifically
interacts with cTnI and causes cTnI phosphorylation at Ser23/24 and Ser150, thus leading
to a reduced Ca2+ sensitivity of contractile regulation. Furthermore, we demonstrated that
IGF-1, a peptide growth factor that has been shown to stimulate myocardial contractility and
protects cardiac injury [24, 25], significantly induces cTnI phosphorylation at Ser23/24 and
Ser150 in a Pim-1 dependent manner in cardiomyocytes. Collectively, these results suggest
that cTnI phosphorylation by Pim-1 may represent a novel mechanism underlying the Pim1-mediated protective effects in the heart.
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Materials and Methods
Cell culture
Human embryonic kidney cells HEK293T and Ad293 cells (ATCC) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS (GIBCO), 1% penicillin/streptomycin (GIBCO) in a
humidified atmosphere of 5% CO2 at 37°C.

Animal model of diabetes
Wild-type (WT) and db/db mice on C57BLK6/J background were obtained from Jackson Laboratory.
Animals were fed either regular chow diet or high fat diet (HF) from 8 week old to 16 week old as described
previously [26]. Mice were sacrificed by inhalation of CO2 for the collection of the heart. This study was
reviewed and approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University.
Isolation of adult rat ventricular myocytes
Ventricular myocytes were isolated from the hearts of adult male Sprague-Dawley rats by collagenasebased enzymatic digestion, as described previously [15]. In brief, hearts were excised and perfused for 5
min with modified HEPES-Krebs solution (pH 7.3 at 37°C) containing (in mmol/L) NaCl 130, MgCl2 4.5,
NaH2PO4 0.4, CaCl2 0.75, HEPES 4.2, taurine 20, creatine 10 and glucose 10. The buffer was saturated with
95% O2/5% CO2 (pH 7.4, 37°C). Hearts were then consecutively retrogradely perfused with Ca2+-free HEPESKrebs solution containing 100 μmol/L EGTA (4 min) and HEPES-Krebs solution containing 100 μmol/L
CaCl2 and 1 mg/mL type II collagenase (Worthington, Lakewood, USA). Hearts were then removed from
the perfusion apparatus, the ventricles cut into small pieces, and isolated myocytes were separated from
undigested ventricular tissue by filtering through nylon gauze, and the latter was incubated in 30 mL of the
collagenase solution for a further 8 min. This step was repeated, thereby generating three isolated myocyte
fractions. In each fraction, myocytes were allowed to settle into a loose pellet and the supernatant was
removed and replaced with HEPES-Krebs solution containing 1 % BSA and 500 μmol/L CaCl2. Myocytes
were again allowed to settle, the supernatant removed and the cells finally pooled and resuspended in 30
mL of HEPES-Krebs solution containing 1 mmol/L CaCl2. The pooled isolated myocytes were pelleted by
brief centrifugation at 50g and washed at room temperature.
Co-immunoprecipitation of cTnI and Pim-1 in HEK293T cells and heart tissues
HEK293T cells were transiently transfected with Flag-tagged cTnI and Myc-tagged Pim-1 expression
plasmids using PEI following our standard protocol for 48 hours. HEK293T cells or rat heart tissues were
lysed or homogenized in a buffer containing 50 mM Tris/HCl (pH 8.0), 1% Nonidet P40, 150 mM NaCl
and protease inhibitors. Co-immunoprecipitation of cTnI and Pim-1 was performed as described previously
[27]. The following antibodies and beads were used for detection and immunoprecipitation: rat polyclonal
anti-Myc antibody (Genescript), mouse monoclonal anti-FLAG antibody (Genescript), rabbit monoclonal
anti-Pim1 antibody (Santa Cruz) and rabbit monoclonal anti-TnI antibody (Cell Signaling), anti-c-Mycagarose affinity gel (Sigma) and anti-FLAG M2-agarose (Sigma).

Immunoblotting
Cell lysates were made using RIPA buffer (Thermo Scientific) containing 25 mM Tris-HCl pH 7.6, 150
mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS and proteinase inhibitor cocktail containing 2 mM
PMSF, 20 μg/mL aprotinin, 10 μg/mL leupeptin. After 1 h extraction with rocking at 4°C, insoluble material
was removed by centrifugation. Supernatants were resolved by SDS-PAGE, and transferred to nitrocellulose
membranes (Bio-Rad), which were blocked with 5% non-fat milk in PBS with 0.1% Tween 20 (PBS/T)
and then incubated with diluted antibodies overnight at 4°C with agitation. After washing with PBS/T for
three times, membranes were incubated with appropriate secondary antibodies (Thermo Scientific). Blots
were visualized on an Odyssey Imaging System (LI-COR) as we described previously [28]. The following
antibodies were used for detecting phosphorylated TnI: anti-phospho-Troponin I (Cardiac) (Ser23/24)
antibody (Cell Signaling), Troponin I Type 3 (cardiac) [p-Ser150] Antibody (Ser150) antibody (Novus).
Immunofluorescent staining
The myocytes cultured on the laminin-coated glass coverslips were fixed with 4% paraformaldehyde for
10 min, washed three times in PBS, and then permeabilized with 0.25%Triton-X100 for 15 min. Following a
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blocking step with 10% of goat serum in PBS for 60 min, the cardiomyocyte were co-immunostained with a
rabbit monoclonal primary antibody against cTnI (1:200, Cell Signaling) and a mouse monoclonal antibody
against Pim-1 (1:200, Santa Cruz) for overnight at 4°C. After washing three times in PBS for 10 min, cells
were stained with TRITC-conjugated anti-rabbit IgG and FITC-conjugated anti-mouse IgG second antibodies
at 1:250 (Invitrogen, USA), respectively, at 37 ºC for 2 h and then were rinsed three times with PBS. Cell
nuclei were stained with DRAQ5. The stained cells were observed by laser-scanning confocal microscopy
(Leica, Heidelberg, Germany).

In vitro phosphorylation assays
Recombinant human cTnI, human troponin complex (Prospec, East Brunswick, NJ), skinned myocyte
were incubated with active recombinant Pim-1 (EMD Millipore) and 100 μmol/L 32P-ATP (PerkinElmer) in
a kinase assay buffer containing (in mmol/L) Tris-HCl (pH 7.5) 25, beta-glycerophosphate 5, dithiothreitol
(DTT) 2, Na3VO4 0.1, MgCl2 10 for up to 120 min at 37 °C as we described previously [28]. The reaction was
terminated by the addition of 0.5 volumes of 3×Laemmli sample buffer and incubated at 95 °C for 5 min, and
then resolved by SDS/PAGE (12% gels) and autoradiography. For western blot analysis, recombinant cTnI
or its mutants was phosphorylated by incubating with active Pim-1 in the presence of non-radiolabelled
ATP (500 μmol/L).

Identification of phosphorylation sites by mass spectrometry
Peptides contained Ser23/24 and Ser150 (APIRRRSSNYRA and TLRRVRISADAM) were synthesized
by Genscript. Peptides were incubated with active Pim-1 in the presence of non-radiolabelled ATP (500
μmol/L) at 30 °C for 60 min. For peptide mass spectrometry analysis of the tryptic digestion products, 50 μL
of the solution was analyzed by LC-MS, using an HPLC system (Series 1100, Agilent Technologies) coupled to
an electrospray ionization mass spectrometer (Finnigan LCQ Advantage MAX, Thermo Electron Corp.). For
HPLC separation of the peptides, a CC 250/4 Nucleosil 100-5 C18 Nautilus column (Macherey-Nagel GmbH)
was used, with a linear gradient over 60 min of 0-65 % solution B in solution A (solution A, 0.1 % formic acid
in water; solution B, 0.1 % formic acid in acetonitrile). Mass spectra were analyzed using Finnigan Xcalibur
software (Thermo Electron Corp.) and the peptide masses assigned, using ExPASy software.

Expression of cTnI mutants and immunoprecipitation kinase assay
Mutants of Flag-tagged cTnI plasmids (Ser23/24→Ala23/24, TCC/TCC→GCC/GCC; Ser42/44→Ala42/44,
TCC/TCG→GCC/GCG; Thr143→Ala143, ACC→GCC; Ser150→Ala150, TCT→GCT) were generated using QuickChange II kit as described by the manufacturer (Agilent). Wild type or mutated plasmids were transiently
transfected into HEK293T cells and lysed with IP lysis buffer. Immunoprecipitation was performed as
described previously [27]. In brief, cell lysates were incubated with anti-Flag M2-agarose (Sigma) overnight
at 4°C with rotation. Agarose beads were centrifuged for 30 sec at 4°C, followed by three times washing
with 500 μl of 1X kinase buffer. The beads pellets were resuspended in 20μl 1X kinase buffer supplemented
with 100 μmol/L 32P-ATP (PerkinElmer) and active Pim-1 protein and then incubated 60 min at 30°C. The
reaction was terminated by the addition of 0.5 volumes of 3×Laemmli sample buffer and incubated at 95 °C
for 5 min, and was then resolved by SDS/PAGE (12% gels) and autoradiography.
Skinned myocyte preparation
Skinned myocyte was prepared as described previously with modifications [21]. Hearts from SpragueDawley rats were excised and immersed in ice-cold relaxing solution, containing (in mmol/L) EGTA 10,
2-[N,N-Bis(2-hydroxyethyl)amino] ethanesulfonic acid (BES) 100, potassium proprionate 55, ATP 5,
creatine phosphate 10, free Mg2+ 1, and protease inhibitor. The myocardial tissue was homogenized in a
Waring blender (~10 s in ice cold relaxing solution) and, following centrifugation (1400 rpm, 1 min), the
myocyte pellet was re-suspended in Triton X-100 (1 % v/v in relaxing solution) for 10 min, to disrupt lipid
membranes. Following two further cycles of similar centrifugation and re-suspension, the myocyte pellet
was washed, re-suspended and kept in ice-cold relaxing solution, until used for in vitro phosphorylation
assays or mechanical measurements.
Functional studies in skinned myocyte fragments
Rat skinned cardiac muscle fibers were pre-incubated with or without 0.1 mg/ml Pim1 in a relaxing
solution for 30 min. Force measurement was performed as previously described [14]. For mechanical
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measurements, myocyte fragments were clamped to a sensitive force transducer (Model 403A, 200 mV/
mg, Cambridge Technology, Inc.) and a high-speed length controller (Model 308B, Aurora Scientific, Inc.)
at either end. All mechanical experiments were performed at 18 °C. Sarcomere length was acquired (240
Hz CCD camera) and analyzed using commercial software (IonOptix Corp.). The sarcomere length was set
to ~2.0 μm in relaxing solution for all functional measurements. Solution changes were made using a fast
stepper motor attached to 2 parallel capillary tubes (Model SF-77B Perfusion Fast-Step, Warner Instrument
Corp.). pClamp software (Axon Instruments) was used to trigger the stepper motor for solution changes
or to impose rapid length changes on the myocyte fragment. Force and length signals were recorded on
a computer using a 12-bit analog/digital board, sampling at 2 kHz. Skinned myocytes were activated in
solutions (pH 7.0) containing a Ca2+ concentration ranging between 10-9 (pCa 9.0; relaxing solution,
composition as given above) and 10-4.5 mol/L (pCa 4.5; maximal Ca2+ activating solution), to measure the
Ca2+ sensitivity of myofilaments.
Statistical analyses
Data are expressed as means ± SE. The statistical significance of differences was assessed by Student’s
t-test or analysis of variance (ANOVA) with Bonferroni’s post hoc test, as appropriate; a value of P < 0.05 was
considered statistically significant.

Results

Interaction of Pim-1 with cTnI
To elucidate the mechanism underlying the regulation of cardiac contractility by Pim-1
[8, 29], we attempted to investigate whether the cardio-protective kinase Pim-1 interacts
with cTnI. In this regard, Myc-tagged human Pim-1 and Flag-tagged human cTnI plasmids
were co-transfected into HEK293T cells, co-immunoprecipitation was then performed.
As shown in Fig. 1A, immunoprecipitation of Myc-tagged Pim-1 led to co-precipitation of
FLAG-tagged cTnI. Similarly,
immunoprecipitation of FlagA
IP
B
tagged cTnI resulted in the
IP: anti-Flag
IP: anti-Myc
Myc-Pim1
IgG Anti-Pim1
+
+
Flag-cTnI
+
+
co-immunoprecipitation
of
Flag-cTnI
+
+
Myc-Pim1
Anti-cTnI
IB
Myc-tagged Pim-1 (Fig. 1A). To
Anti-Myc
Anti-Flag
IB
Anti-Pim1
IB
Anti-Flag
determine whether there is an
Anti-Myc
Anti-cTnI
endogenous interaction of cTnI
Input
Anti-Pim1
Anti-Myc
Anti-Flag
and Pim-1 in cardiomyocytes,
Input
Input
Anti-Flag
Anti-Myc
we performed co-immunoprecipitation with anti-Pim-1
C
antibody using mouse heart lysates. As shown in Fig. 1B, cTnI
co-precipitated with the antiPim-1 antibody, but not with the
nonimmune IgG. To investigate
the intracellular localization of
this interaction, we performed
Pim1
cTnI
Merge
immunofluorescent staining in
Figure 1
adult mouse cardiomyocytes. Fig. 1. Interaction of Pim-1 with
cTnI. (A). HEK293T cells were
Immunofluorescent microscopy co-transfected with Flag-cTnI and Myc-Pim-1. Co-immunprecipishowed a strong colocalization tation were performed by using anti-Flag or anti-Myc antibodies
of Pim-1 and cTnI in the sarco- and then analyzed by western blot. (B). Adult mouse heart tismere of cardiac cells (Fig. 1C). sue samples were extracted and immunoprecipitated with either
Together, these results indicate anti-Pim-1 antibody or control IgG and then analyzed by western
that Pim-1 interacts with cTnI blot. (C) Fixed adult mouse cardiomyocyte were stained with antiin cardiomyocytes under physi- Pim-1 and anti-cTnI antibodies and then processed for fluorescent
ological conditions.
staining analysis.
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determine the phosphorylation
kinetics of troponin complex by
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cTnI in the troponin complex
in a time-dependent manner,
while TnT was also phosphorylated by Pim-1 in the Tn complex (Fig. 2C). Taken together,
these results suggest that cTnI
is a good substrate of Pim-1 kinase.
Because Pim-1 preferentially phosphorylates the
consensus sequence (K/R)(K/R)-(K/R)-X-(S/T)-X
[30],
and phosphorylation of several
serine/threonine sites in cTnI
has been reported to play important roles in regulation of
cardiac contraction/relaxation.
We attempted to map the Pim1induced phosphorylation sites
in cTnI by a site-directed mutagenesis of Ser (S) to Ala (A)
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Verification of the phosphorylation Fig. 5. Effects of Pim-1-mediated phosphorylation on Ca2+sites by MALDI–TOF-MS
sensitive tension development in skinned myocytes. (A).
To further confirm the Pim-1-in- Pim-1-mediated cTnI phosphorylation in skinned myoduced phosphorylation sites in cTnI, cyte preparations, as detected by western blot and quantwo peptides derived from cTnI span- titated by densitometric analysis. Equal protein loading is
ning the potential phosphorylation indicated by actin on coomassie-stained gels. ** P<0.01 vs
residues of Ser23/24 and Ser150 were non-treatment group. (B). Relative maximum force develsynthesized, respectively, and then opment by skinned myocytes in the presence or absence
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etry. As shown in Fig. 4A and 4B, both (n=5 per group).
peptides were efficiently phosphorylated at Ser23/24 and Ser150 by Pim1,
further indicating that Pim1 could potentially phosphorylate cTnI at Ser23/24 and Ser150.
Figure 5

Pim-1 regulates cardiac myofilament function
To determine the effect of Pim1-induced cTnI phosphorylation on cardiac myofilament
activity, we first investigated whether Pim1 phosphorylates cTnI Ser23/24 and Ser150
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Fig. 6. Pim-1 is involved in IGF-1-induced cTnI phosphorylation in cardiomyocytes. (A). Rat ventricular
cardiomyocytes were stimulated with IGF-1 (20 ng/ml) at different time points (A) and doses for 60 min
(B), phosphorylation levels of cTnI at Ser23/24 and Ser150, total cTnI, and Pim-1 were detected by western
blot and quantitated by densitometric analysis. * P<0.05; ** P<0.01 vs basal level. n=3. (C). Cardiomyocytes
were treated with SMI-4a (10 µM), LY294002 (30 μM) or H89 (10 µM) for 1 hr, followed by stimulating with
IGF-1 (20 ng/ml) for 2 hr, phosphorylation levels of cTnI at Ser23/24 and Ser150, total cTnI, and Pim-1 were
detected by western blot and quantitated by densitometric analysis. * P<0.05 vs. CTL. # P<0.05 vs. IGF-1
treated group. SMI-4a, Pim-1 inhibitor; LY294002, PI3K inhibitor; H89, PKA inhibitor.

residues in skinned fibers from the adult rat left ventricle. As expected, there was a significant
increase in the phosphorylation of Ser23/24 and Ser150 after a 60-minute exposure of
the skinned fiber preparation to active Pim1, indicating that cTnI is a natural substrate of
Pim1 and Pim1 may regulate Ca2+ sensitivity in skinned myocardial preparations (Fig. 5A).
Then, we determined whether Pim-1-mediated cTnI phosphorylation affects myofilament
contractility and calcium selectivity in skinned myocytes from the adult rat left ventricle.
Although there was no significant difference between the control and Pim1-treated groups
in maximum force and Hill coefficient (nH) (Fig. 5B), Pim1-mediated phosphorylation of
cTnI significantly reduced the Ca2+ sensitivity of skinned myocardial fibers, resulting in a
rightward shift of the force-pCa curve (Fig. 5C). As shown in Fig. 5D, pCa at 50% maximal
tension (pCa50) was 5.912 ± 0.029 in the control group (n=4) and 5.760 ± 0.010 in the
Pim1-treated group (n=5; P<0.05), suggesting that there was a reduction of Ca2+ sensitivity
of Pim1-modified skinned fiber preparations.

IGF-1 phosphorylates cTnI through inducing expression of Pim-1 in cardiomyocytes
Insulin like growth factor 1 (IGF-1) has been shown to stimulate cardiac growth and
contractility and exert protective effects in the heart, although the mechanism of this
effect still remains elusive [25]. Interestingly, IGF has recently been shown to potently
induce Pim1 expression in the heart [8], which prompted us to speculate that IGF-1 may
regulate cardiomyocyte contractility via Pim-1-induced cTnI phosphorylation. To test this
hypothesis, rat ventricle cardiomyocytes were stimulated with IGF-1 and phosphorylation
of cTnI at Ser-23/24 and Ser-150 were then determined by western blot. Indeed, consistent
with a previous report [8], IGF-1 treatment of cardiomyocytes markedly induces Pim-1
expression, which parallels the increased phosphorylation of cTnI at Ser23/24 and Ser150
in cardiomyocytes (Fig. 6A and 6B). To further determine the molecular signaling pathway
(s) involved in IGF-1-induced cTnI phosphorylation, several pharmacological inhibitors of
protein kinases were utilized. As shown in Fig. 6C, pretreatment of cardiomyocytes with
PKA inhibitor H89 barely affected IGF-I-induced cTnI phosphorylation, while inhibition
of AKT pathway with LY294002 partially, but significantly, blocked IGF-1-induced cTnI
phosphorylation. Importantly, pretreatment of cardiomyocytes with SMI-4a, a Pim-1 specific
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inhibitor [30], almost completely blocked IGF-1-induced cTnI phosphorylation, suggesting
that IGF-1-induced cTnI phosphorylation in cardiomyocytes is Pim-1 dependent.

Implication of the Pim1/cTnI axis in diabetic cardiomyopathy
Our previous studies have shown that the expression of Pim-1 is dramatically
downregulated in diabetic mouse heart tissues [30]. Furthermore, the cardiac contractility
and cTnI phosphorylation have been shown to be significantly reduced in diabetic hearts
[31, 32]. To further substantiate the pathophysiological significance of Pim-1-induced
cTnI phosphorylation, we determined whether Pim-1 expression is correlated with cTnI
phosphorylation in vivo. In this regard, Pim1 expression and cTnI phosphorylation levels
were analyzed in heart homogenates from the diabetic db/db mice fed with a HF and
their normal controls by western blot analysis. As shown in Fig. 7A and 7B, consistent
with previous reports [30, 33], the expression of Pim-1 was significantly decreased in the
diabetic hearts. Likewise, the phosphorylation levels of cTnI at Ser23/24 were markedly
reduced by approximately 60%, while the phosphorylation of cTnI at Ser150 was slightly,
but statistically significantly, decreased by approximately 25%, as compared to their normal
controls (Fig. 7C). Together, these results suggest that decreased Pim1 expression with a
resultant reduction of cTnI phosphorylation in the heart might play important roles in the
development of diabetic cardiomyopathy.
Discussion

Covalent modification of cTnI by kinase-mediated phosphorylation is an important
mechanism in the regulation of thin filament function and thereby the cardiac contractile
phenotype [11, 12]. Furthermore, altered phosphorylation of cTnI and other myofilament
proteins have been shown to contribute causally to the cardiac dysfunction in the
transition from compensated hypertrophy to heart failure [23]. Thus far, several protein
kinases, including PKA, PKC, AMPK, and PKD, have been shown to phosphorylate cTnI and
regulate myofilament activity [34, 35]. In the present study, we provide the compelling
evidence implicating Pim-1 as a novel protein kinase that specifically interacts with and
phosphorylates cTnI at Ser23/24 and Ser150 in the heart. Indeed, Pim1 and cTnI were found
to colocalize in adult cardiomyocytes. The functional consequence of this interaction was
demonstrated by the ability of Pim1 to induce cTnI phosphorylation and reduce myofilament
calcium sensitivity. Indeed, IGF-1, a cardiac protective hormone that has been shown to
increase cardiac contractility, increases Pim-1 expression and cTnI phosphorylation cardiac
cells. These results suggest that the phosphorylation of cTnI by Pim1 may be an important
determinant of cardiac myofilament activity.
Recently the pathophysiological roles of Pim-1 in the heart have received a significant
attention. Both loss- and gain-of-function studies have implicated Pim-1 as an essential
kinase in the regulation of cardiomyocyte survival, calcium dynamics, cardiac contractility,
and mitochondrial function in cardiomyocytes. For instance, cardiac specific overexpression
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of Pim-1 has been shown to decrease infarct size and maintain contractility after myocardial
infarction [2, 29], whereas Pim-1 knock out displayed a significant prolongation of calcium
decay and the sarcomeric relaxation period and this was accompanied by a decrease
in sarcoendoplasmic reticulum Ca2+ATP-ase (SERCA) and sodium-calcium exchanger
(NCX) expression [8]. However, it is still unknown whether Pim-1 regulates cardiac
myofilament function by posttranslational modulation of sarcomere proteins. Indeed, our
coimmunoprecipitation and colocalization assays demonstrated a direct binding of Pim1 with cTnI in cardiac cells, which led us to further investigate whether Pim-1 regulates
myofilament activity through phosphorylating cTnI. In vitro phosphorylation assays showed
that cTnI was robustly phosphorylated by Pim-1 in a time and dose dependent manner. To
our knowledge, this is the first evidence demonstrating cTnI as a natural substrate of Pim-1
kinase in cardiomyocytes. Furthermore, by applying a site directed mutagenesis strategy
and mass spectrometry analysis, we demonstrate that Pim-1 phosphorylates cTnI primarily
at Ser23/24 and at Ser150. Furthermore, our in vitro study shows that Pim-1 preferentially
phosphorylates cTnI at Ser23/24, and the precise mechanism underlying this process is
unknown. We speculate that once Pim-1 binds to cTnI, it will cause a conformational change
of cTnI that favors the binding of Pim-1 to the site of Ser23/24. It is well established that
phosphorylation of cTnI at different sites results in different myofilament function [34]. For
example, both PKA and PKD have been shown to phosphorylate cTnI at Ser23/24, which
resulted in a reduction of Ca2+ sensitivity and acceleration of relaxation and crossbridge
cycle kinetics [13-15]. In contrast, p21-activated kinase (PAK), which phosphorylates cTnI
at Ser150, has been shown to increase Ca2+ sensitivity [19]. Furthermore, AMPK, which
causes a cTnI phosphorylation predominantly at Ser150 as compared to Ser23/24, has been
shown to increase myofilament Ca2+ sensitivity and prolong cardiac relaxation [21, 22]. In
the present study, we herein provided a novel phosphorylation pattern of cTnI as regulated
by cardioprotective Pim-1 kinase in the heart. Indeed, our biochemical assays showed that
compared to Ser150, Pim-1 preferentially phosphorylates cTnI at Ser23/24, leading to
a reduction of myofilament Ca2+ sensitivity. It should be noted that the change of cardiac
myofilament Ca2+ sensitivity does not always correlate with the change of maximum force.
For example, J van der Velden et al. reported that the maximum force was not significantly
changed, but the Ca2+ sensitivity was significantly increased in end-stage failing hearts, which
may be attributed to the altered phosphorylation of contractile proteins such as myosin light
chain 2 (MLC-2) and cTnT [36]. In our study, we also found that in addition to cTnI, cTnT may
also function as a substrate of Pim-1 in the heart, which may contribute to the reduced Ca2+
sensitivity and unchanged maximum force.
Insulin-like growth factor I (IGF-I) is an important growth factor for cell differentiation
and proliferation [37]. In the heart, it has been shown to stimulate cardiac growth and
increase contractile function [24, 25]. Moreover, cardiac specific overexpression of IGF-1 has
been shown to reduce myofilament isometric tension and increase cTnI phosphorylation,
through a yet unknown mechanism [38]. Recently, IGF-1 has been found to potently induce
Pim-1 expression in cardiomyocytes [8]. In our study, we found that Pim-1 increases cTnI
phosphorylation at Ser23/24 and Ser150 in a Pim-1- dependent manner in cardiomyocytes.
In this regard, our studies provided a novel mechanism by which IGF-1 may exert some of its
cardioprotective effects through regulation of cTnI phosphorylation and myofilament activity
in the heart. Previously, Akt has been shown to be essentially involved in the induction of
Pim-1 expression by IGF-1 in the heart [8]. Consistent with this finding [8], treatment of
cardiomyocytes with AKT inhibitor LY294002 markedly, but not completely, blocked IGF-1induced cTnI phosphorylation, indicating that other molecular pathways may be involved in
the IGF-1-induced Pim-1 expression and cTnI phosphorylation in the heart, which warrants
further investigation. Indeed, in a diabetic cardiomyopathy model, it has been shown that
the changes in myocardial pAkt and Pim-1 levels were not synchronous, with Pim-1 starting
to decrease earlier than pAkt [39]. At this point, the molecular mechanism(s) responsible
for Pim-1 downregulation in DCM remains elusive. Decreased phosphorylation of STAT3
and increased expression of protein phosphatase 2A (PP2A), have been reported to mainly
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contribute the regulation of Pim-1 expression at transcriptional and posttranslational levels
in the diabetic hearts [7, 39].
It is well established that diastolic dysfunction is the most prominent defect of diabetic
cardiomyopathy, which is characterized by decreased compliance, prolonged myocardial
relaxation, and altered intracellular Ca2+ homeostasis [40]. In streptozotocin (STZ) induced
diabetic cardiomyopathy, reduced SERCA2a expression is still not sufficient to explain the
contractile deficit [41]. In this study, we found that Pim-1 expression was significantly
reduced in diabetic hearts, which is consistent with previous published studies [39].
Moreover, this reduction was accompanied by decreased phosphorylation levels of Ser23/24
and Ser150, suggesting that Pim-1 may represent an important upstream kinase responsible
for modulating cTnI phosphorylation in diabetic cardiomyopathy. Indeed, several studies
have shown that IGF-1 levels are significant reduced under diabetic conditions [42-44].
These results suggest that preservation of IGF-1/Pim-1 pathway in the heart may represent
a novel therapeutic strategy to prevent the development of diabetic cardiomyopathy.
Conclusion

In summary, we have shown that Pim-1 is a novel kinase that interacts with cTnI in
cardiomyocytes. This interaction is relatively specific, as it causes cTnI phosphorylation; it
is functional, as it leads to a reduction of myofilament Ca2+ sensitivity; and it is physiological,
as it may mediate the cardioprotective effects of IGF-1 on cardiomyocytes. These findings
suggest that Pim-1 may be an important therapeutic target for promoting cardiac muscle
contractility under various pathophysiological conditions, such as diabetic cardiomyopathy
and heart failure.
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